Podcasts about Adjunct

I've been browsing old compur surveys and trying to build up a comprehensive data set. What I've found is a little surprising: between late 1945 and 1949 only 10 new computers entered service. Once we get to the 50s that number explodes. What's going on here? What caused the gap between the first digital machines and the explosion of computers in the 50s? In this episode I try to answer that question by finding out just what was going on during this digital gap. Like Advent of Computing? Then check out the after show! Adjunct of Computing is now LIVE: YouTube Spotify Apple Podcasts

Could ketogenic therapy help people with schizophrenia spectrum disorders engage more successfully with CBT? A new conceptual framework explores this powerful adjunctive approach.CBTp is considered a gold-standard treatment for schizophrenia spectrum disorders, but many patients struggle to initiate, participate in, and complete it. Cognitive deficits, sleep disturbances, low distress tolerance, and ongoing psychotic symptoms can all stand in the way. In this conversation, Dr. Bret Scher sits down with licensed clinical social worker Nicole Laurent to discuss her recently published paper in Frontiers in Psychology, exploring how ketogenic metabolic therapy could help bridge that gap.In this conversation, you'll learn:Why CBTp is so cognitively demanding and where patients tend to struggleHow ketogenic therapy may reduce key barriers like sleep issues, distress tolerance, and cognitive impairmentWhat a conceptual analysis paper is and why it matters for shaping future researchHow clinicians and researchers can begin integrating these ideas into practiceWhether this framework could extend to CBT for depression, OCD, and anxietyThis discussion opens the door to thinking about ketogenic therapy not only as a direct treatment for psychiatric symptoms, but as a powerful adjunctive tool that could help patients engage more fully with the rest of their care.

On this episode, I speak wtih Léonard Boussioux — Assistant Professor, Foster School of Business; Adjunct, Paul G. Allen School of Computer Science & Engineering, UW. PhD, MIT (machine learning & operations research). Co-founder of Universal AI. "Professor Leo," as his students call him, is a leader in AI education, research, experimentation, and adoption. He and I are on the Foster AI Taskforce, and sat down for this conversation in August of 2025. Leo rejects the career advice you've heard your entire life: pick a lane, specialize, go deep. His counter-argument is that AI now lets you be — in his words — a specialist of everything. In this conversation, we dig into what that actually means for MBA students, career switchers, and anyone trying to figure out how to use AI without offloading their thinking to it. We cover how Leo teaches non-coders to ship working products in a single class session, how he uses six different AI models to plan a vacation (and why), the new category of jobs emerging around human-AI collaboration, and why the people who panic about AI are usually the ones who haven't played with it yet. 3 Key Takeaways 1. Drive the AI. Don't delegate to it. The students who get worse at thinking are the ones who treat AI as a ghostwriter. The ones who get sharper treat it as a collaborator — pushing it in specific directions, rejecting outputs, iterating.  2. Build something this weekend. Reading about AI is not learning AI. Leo's students — most with zero coding background — ship working websites and games in a single class. Vibe coding tools like Lovable have collapsed the gap between idea and prototype to minutes. If you're an MBA recruiting into product, strategy, or consulting, the ability to prototype your own thinking is now a baseline skill, not a bonus. 3. The new jobs are at the human-AI seam. Automation creates a new category of work: deciding where humans belong in the loop, designing the workflows, catching the 5% of edge cases that have outsized consequences. Moderator, orchestrator, AI workflow consultant — these roles barely existed two years ago. Position yourself there. Learn more about Leo at https://leobix.com, or on LinkedIn.

Probiotics: A Promising Adjunct to Non-surgical Periodontal Therapy?By Today's RDH ResearchOriginal article published on Today's RDH: https://www.todaysrdh.com/probiotics-a-promising-adjunct-to-non-surgical-periodontal-therapy/Need CE? Start earning CE credits today at ⁠⁠⁠https://rdh.tv/ce⁠⁠⁠ Get daily dental hygiene articles at ⁠⁠⁠https://www.todaysrdh.com⁠⁠⁠ Follow Today's RDH on Facebook: ⁠⁠⁠https://www.facebook.com/TodaysRDH/⁠⁠⁠Follow Kara RDH on Facebook: ⁠⁠⁠https://www.facebook.com/DentalHygieneKaraRDH/⁠⁠⁠Follow Kara RDH on Instagram: ⁠⁠⁠https://www.instagram.com/kara_rdh/⁠

Featuring proceedings from a live event on January 9, 2026, held adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium and moderated by Dr Samuel J Klempner, including the following topics: Treatment approach for metastatic HER2-negative, claudin 18.2-positive, microsatellite instability-high gastroesophageal (GE) cancer (0:00) Duration of chemotherapy for patients with advanced GE cancers receiving nivolumab/chemotherapy (3:06) Younger patient with metastatic PD-L1-positive gastric cancer (5:29) CME information and select publications

What connects IBM, the NSA, the Third Reich, and high fidelity recordings of symphonies? The answer is: magnetic drum memory. Join me as I lose all track of scope and plot to discovery just how and why magnetic drum memory was invented. Like Advent of Computing? Then check out the after show! Adjunct of Computing is now LIVE: YouTube Spotify Apple Podcasts

There was a time when "adjunct" meant "cheap beer." One of America's largest breweries even paid millions of dollars to run television commercials during the Super Bowl accusing another of America's largest breweries of using worse adjuncts than they themselves used.Oh, what a world!But for craft breweries, an ingredient is an ingredient. What if adjuncts added flavor?  What if adjuncts actually cost more than malted barley?  What if adjuncts could tell a story of time and place?Corn and rice aren't cheap anymore.  They have a history.  They tell a story.  And good breweries know how to use ingredients to tell the story of great beer. Visit AllAboutBeer.com for more podcasts, to read original articles, and to get info on upcoming events.Click here to support independent journalism covering the beer industry.This Episode is Sponsored by:All About BeerAt All About Beer, we're honored to share the stories that define the beer community, and we couldn't do it without the generous support of our underwriting sponsors. Their commitment helps sustain independent beer journalism, allowing us to highlight the people, places, and passion behind every pint. Their partnership ensures these stories continue to inspire, connect, and celebrate the craft we all love. Join our underwriters today and help make an impact on independent journalism covering the beer industry.Host: Don TseGuests: Doug Reiser, Tom Beckmann, Chris PiscitelloSponsors: All About BeerTags: Rice, Corn, Brewing Photo: by Don Tse

From the very earliest days of what we now know as craft beer, flavor has been a defining factor and a guiding mantra for brewers casting themselves against the monolith of light macro lager that dominated American brewing for so many decades. If you track it back, fruits and spices have been ingredients in beer for as long as beer has been made, so this modern era of craft brewing is more rediscovery than revolution. But there's no denying that familiar and enticing, or even exotic and intriguing, flavors have been an incredible draw in bringing people into the fold who might never have considered themselves beer drinkers. Of course, the ways we can add those fruit and spice flavors to beer have evolved significantly from the earliest days of craft brewing, and brewers now have tools to target and dial in fruit and spice notes with incredible precision—something that is increasingly important as brewers explore low-ABV and nonalcoholic beers and beverages. In this episode, produced in partnership with Amoretti, we explore best practices for delivering flavor impact that's noticeable, authentic, seamless, and artful, but that also works to support the bottom line for breweries facing ever-increasing input costs. Joining the discussion are: Michael Lalli, brewmaster, Krebs Brewing and Prairie Artisan Ales (Krebs, Oklahoma) Micah Rush, R&D manager, The Bruery and Offshoot Beer (Placentia, California) Nic Bortolin, brewmaster and brand ambassador, Amoretti To connect directly with Nic Bortolin for questions or more information, please email him at Nic@amoretti.com.

Attia Qureshi examines negotiation not simply as a business skill, but as a core leadership capability that shapes influence, alignment, and decision-making. Drawing on experience across consulting, startups, academia, and international development, she explains why many capable professionals struggle in negotiations despite strong analytical skills. The discussion explores several practical themes: why preparation is often undervalued, how fear and emotional reactions affect judgment under pressure, and why negotiation should be treated as a skill built through repetition rather than theory alone. Qureshi also distinguishes influence from manipulation, emphasizing that durable cooperation is built through trust, reciprocity, and understanding shared interests. The episode covers organizational alignment, stakeholder management, rejection, and emotional resilience, including lessons from work in Colombia helping farming communities transition away from coca production. Throughout the conversation, Qureshi argues that effective negotiators are not necessarily the most aggressive or persuasive, but the ones who can stay disciplined, build trust, and navigate difficult conversations with clarity and composure. This episode offers practical insights for leaders seeking to improve negotiation, relationship management, and organizational effectiveness in both professional and personal settings. Attia Qureshi is an adjunct at the Ford School of Public Policy and previously at MIT's Sloan School of Management and Ross School of Business. The founder of Attia Qureshi Consulting, where she supports companies through negotiation, conflict resolution, and organizational strategy. Get Attia's book, Never Settle, here: https://tinyurl.com/2fyjhb5m Claim your free gift: Free gift #1 McKinsey & BCG winning resume www.FIRMSconsulting.com/resumePDF Free gift #2 Breakthrough Decisions Guide with 25 AI Prompts www.FIRMSconsulting.com/decisions Free gift #3 Five Reasons Why People Ignore Somebody www.FIRMSconsulting.com/owntheroom Free gift #4 Access episode 1 from Build a Consulting Firm, Level 1 www.FIRMSconsulting.com/build Free gift #5 The Overall Approach used in well-managed strategy studies www.FIRMSconsulting.com/OverallApproach Free gift #6 Get a copy of Nine Leaders in Action, a book we co-authored with some of our clients: www.FIRMSconsulting.com/gift

Caroline Bicks joins Writer's Voice to talk about Monsters in the Archives, her fascinating exploration of Stephen King's private papers, creative process, and the deep emotional fears beneath his horror fiction. Then Marie Adelmann discusses Adjunct, her darkly funny and painfully real novel about precarious academic labor, student debt, and the exploitation built into today's university system. Two compelling conversations about fear, power, and survival in contemporary American life.

In 1947 Raytheon signed a contract to make their first computer. It would be their last... at least for many many years. The fruits of this contract was RAYDAC. Early digital computers were odd, to say the least. And RAYDAC distinguishes itself. From zig-zag delay lines to hunting tapes to freon cooling, it truly is a unique machine. Selected Sources: https://ed-thelen.org/McGee_Book-4.2.2.pdf - McGee on his experience programming RAYDAC https://sci-hub.st/10.1109/JRPROC.1948.232626 - A Digital Computer for Scientific Applications https://www.jstor.org/stable/2002859 - The Logical Design of RAYDAC Like Advent of Computing? Then check out the after show! Adjunct of Computing is now LIVE: YouTube Spotify Apple Podcasts

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here.

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00) Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal cancer (8:58) Approach to managing Stage III colon cancer with ctDNA-positive results after adjuvant treatment (13:35) CME information and select publications

Rev. Carolyn Patierno, Adjunct Minister, preaching Worship service given April 26, 2026 Prayer by Rev. Dr. Jonipher Kwong, Interim Lead Minister https://firstparish.info/ First Parish A liberal religious community, welcoming to all First gathered 1739 In honor of Earth Day, we'll consider the ways that Love is centered in the natural world. Guest Musician Alaistair Moock will offer music, along with accompanist Ken Seitz and the First Parish Choir. Offering and Giving First The Giving First program donates 50% of the non-pledge offering each month to a charitable organization that we feel is consistent with Unitarian Universalist principles. The program began in November 2009, and First Parish has donated over $200,000 to more than 70 organizations. For April 2026, The Cambridge Women's Center will share half the offering collected during Sunday worship at First Parish. The Cambridge Women's Center is a physical and digital community space open to anyone for whom woman is a meaningful identifier or lived experience. They offer a safe space for learning, emotional support, empathy, and empowerment through self-determination. Learn more at their website: https://www.cambridgewomenscenter.org/. The remaining half of your offering supports the life and work of this Parish. To donate using your smartphone, you may text "fpuu" to 73256. Then follow the directions in the texts you receive.

With their Cream Ale outselling all of the biggest beers in the LCBO by around 3-4x in the area, Anderson Craft Ales seem to have the unofficial craft beer of London, ON on their hands. Founder Gavin Anderson jumped back on the pod after three and a half years to chat about what's been happening since we last spoke, their upcoming 10th anniversary and some of the craziest beers they've ever done (including glizzy, roast chicken and pizza beers), all of the Anderson classics that they're bringing back from the archives for the anniversary, the evolution of their seasonal beers, why they continue to stick with short cans vs tall cans, why their town and neighbourhood is so important to them, the return of the Black IPA, Gavin's personal IPA renaissance, why they're cool with selling mixed packs of beers versus forced four or six-packs, and the rise of the Cream Ale. We got into six Anderson bangers - Tmavý Ležák 11° Czech-Style Dark Lager, Italian Pilsner, Cream Ale, Kuty Dutch Lager, IPA WCIPA, and Coconut Black IPA. This was a gem - cheers! Get your 10th anniversary party tickets here: https://www.andersoncraftales.ca/product-category/anniversary-party-tickets/ BAOS Podcast Subscribe to the podcast on YouTube | Website | Theme tune: Cee - BrewHeads

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00) Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56) Biomarker assessment approach and treatment selection (10:50) CME information and select publications

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium. CME information and select publications here.

It's not every day we get to speak to someone as accomplished as Christian Klaus Riemerschmid von der Heide. Co-Founder of The Paris Beer Co. in Paris, ON, Christian joined Cee to chat about his upbringing in a small town in Bavaria and how the local brewery is a key part of life, why most German breweries had their own malting facility, his unique beer journey from his first apprenticeship to his Head Brewer position at the esteemed Augustiner-Bräu, his work with Labatt, Diageo and even Guinness, what brought him back to Canada, why they choose to grow and control as many of the ingredients as possible, their hop farms, what their sub-brand Tagwerk represents and how the Tagwerk Farm contributes, how he met the legendary Chuck Hahn in Australia, why he'd rather lose a hand than put marshmallow in a beer, and why he's so dedicated to beer. We got into a bunch of incredible Paris and Tagwerk beers - Tagwerk Tafelbier Bière de Table, Paris Salty Stinger Blue Raspberry Gose, Paris Head Gate Helles Lager, Paris Lazy Dog Helles Bock Festbier, Paris Bumble Mint Honey Weissbier, Tagwerk Smoked Oat Porter, Paris Barnyard Bully Double English IPA, and Hop't Sparkling Hop Water (Tutti Fruitti). Absolute legendary episode - get it in ya! BAOS Podcast Subscribe to the podcast on YouTube | Website | Theme tune: Cee - BrewHeads

The image of a mainframe is almost always accompanied by it's companion: the magnetic tape drive. For decades magnetic tape served as the medium of choice for computing. It was faster than punch cards, and more available than hard drives. But where did it come from? Is it a borrowed technology like the vacuum tube? Like Advent of Computing? Then check out the after show! Adjunct of Computing is now LIVE: YouTube Spotify Apple Podcasts

Enjoy this workshop as we explored forgiveness, flourishing, reconciliation, Catholic Social Teaching, and the work of justice. Featuring Joshua Snyder, Moderator; Guest Editor, C21 Resources Magazine; Associate Professor of the Practice in Theological Ethics at Boston College; Katherine Jackson-Meyer, Research Associate, Human Flourishing Program at Harvard University; Affiliate of the Harvard Medical School Center for Bioethics; and Stephanie Edwards, Executive Director, Boston Theological Interreligious Consortium; Adjunct professor of Theology at Boston College. Date of event: March 26, 2026. Watch the workshop here: https://youtu.be/60OIBQc-lAQ  Learn more about the C21 Center and our resources: Website: https://www.bc.edu/bc-web/centers/church21.html Instagram: https://www.instagram.com/c21center/ Facebook: https://www.facebook.com/C21Center/ Twitter: https://twitter.com/C21Center LinkedIn: https://www.linkedin.com/company/104167883 Questions? Email church21@bc.edu 

Send us Fan MailIn this Journal Club episode, Daphna presents the F-NeoBright trial — a pilot feasibility and safety study out of Hungary exploring intranasal fresh breast milk administration in neonates with moderate to severe HIE undergoing therapeutic hypothermia. With so few adjunct therapies available beyond cooling, the idea of harnessing breast milk's rich bioactive components — including neurotrophic growth factors, cytokines, and multipotent stem cells — to support the developing brain is both compelling and refreshingly low-risk. Daphna walks us through the protocol, the feasibility outcomes, and why 100% of approached families consented, including those who had never planned to breastfeed. Sometimes the simplest intervention really is the right one!----F-NEO-BRIGHT: feasibility and safety of intranasal fresh breast milk in neonatal encephalopathy. Tarjanyi E, Jermendy A, Szabo M, Brandt FA, Szasz B, Nyilas N, Meder U.Pediatr Res. 2026 Mar 3. doi: 10.1038/s41390-026-04847-2. Online ahead of print.PMID: 41776367Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

One of the coolest and most innovative brewery collaborations this decade is Vancouver, BC's Threefold. A shared taproom comprised of three independent breweries - Temporal Artisan Ales, Slow Hand Beer Co., and Boombox Brewing - Threefold is the perfect manifestation of what combining your powers in the craft beer industry can look like. We had a bit of a podcast party, featuring Tristan Stewart of Temporal, Kurtis Sheldon of Slow Hand, and Phil Spurgeon + Kent Courtice of Boombox, and we got into each brewery's origin story and what they all specialize in, how the idea of Threefold came together, the build out of the space and how it fits into the Vancouver's craft beer landscape, how they split the labour, why Tristan brews for all three brands and how he manages it all, how they've built community around the taproom, and where they plan to take it from here. We got into two beers from each brewery - Slow Hand x Nammos Mediterranean Pilsner, Boombox Juicy AF NEIPA, Boombox Cyber Samurai Double NEIPA, Temporal Breezeway Czech Farmhouse Ale collaboration with Four Winds, Temporal Stout, Reconstituted Blended Stout, and Slow Hand Pilsner. This was a phenomenal conversation with three impeccable breweries doing something special - enjoy! BAOS Podcast Subscribe to the podcast on YouTube | Website | Theme tune: Cee - BrewHeads

În acest episod BT Business Talks, Claudiu Pândaru stă de vorbă cu Tiberiu Moisă, Director General Adjunct MidCorporate & IMM la Banca Transilvania, despre rolul leadershipului într-o organizație mare și despre modul în care băncile pot susține dezvoltarea mediului de business. Discuția explorează relația dintre bancă și antreprenori, importanța încrederii în parteneriatele pe termen lung și provocările aduse de transformarea tehnologică din sectorul financiar. Într-un context economic în continuă schimbare, companiile au nevoie nu doar de finanțare, ci și de parteneri care înțeleg dinamica mediului de afaceri și pot contribui la dezvoltarea sustenabilă a acestuia. Un episod despre leadership, adaptare și parteneriate solide într-o economie în continuă transformare.

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Adjuvant treatment planning for Stage II or III microsatellite instability-high colon cancer (0:00) Roles of circulating tumor DNA (ctDNA), POLE mutations and advanced age in adjuvant treatment planning (6:08) Role of ctDNA in adjuvant treatment planning for Stage III colon cancer (12:31) CME information and select publications

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Gastroesophageal cancer (0:00) Recurrent colorectal cancer (5:43) Colorectal cancer with brain metastases (9:59) CME information and select publications

Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.

Our Brewery of the Year for 2024, Niagara Falls, ON's Counterpart has just kept on winning, dropping world-class barrel-aged beers, impeccable hazy IPAs and offering some of the best food options in a brewery in the country. Co-Founder Greg Gnyś jumped back on the pod for the third time to catch up on what's been happening since his last appearance, the opening of their sister pizza spot, Counterpie, how their Flow Fest craft beer festival went down in 2025 and what to expect in 2026, the evolution of their barrel program and how exceptional it is, their recent seventh anniversary releases, why they worked with Western New York breweries for their last anniversary and why they rocked with Quebec breweries this year, the Counterpart x BAOS 10th anniversary collaboration, bottle shares and how Greg gets hold of the best stuff in the US, and how they're growing their footprint across the province. We cracked the entire seventh anniversary lineup - Folklore Czech-style Amber Lager collaboration with Jackalhop, Seven New England Pale Ale, Dead Sea 2 NEIPA collaboration with Le Ketch, Dream Taker Double NEIPA collaboration with Brasserie Sir John, Strange Beast Triple NEIPA collaboration with Nano Cinco, Empire (Macadamia Nut) Imperial Pastry Stout collaboration with Brasserie du Bas-Canada, Empire (Hazelnut Coffee) Imperial Pastry Stout collaboration with Brasserie du Bas-Canada, Zombie Party (Smooth Libre) Smoothie Sour collaboration with Brasserie du Bas-Canada and Brasserie Sir John, and Zombie Party (Tropics Syrup) Smoothie Sour collaboration with Nano Cinco and Jackalhop. This was a banger - cheers! BAOS Podcast Subscribe to the podcast on YouTube | Website | Theme tune: Cee - BrewHeads

In which we discuss GPSS: the General Purpose Simulation Language. As for as languages go, this is a unique one. It's designed for certain types of simulations. It's code is just a handy way to feed a flowchart into a computer. It's design is closer to an analog computer than it is to a programming language. Yet GPSS is Turing Complete. Step inside and prepare to be... confused! The big source of the show: https://dl.acm.org/doi/epdf/10.1145/960118.808382 - The Development of GPSS Like Advent of Computing? Then check out the after show! Adjunct of Computing is now LIVE: YouTube Spotify Apple Podcasts

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Older patient with metastatic claudin 18.2-positive gastroesophageal (GE) cancer (0:00) Management of nausea and vomiting with zolbetuximab for GE cancer (9:37) Younger patient with metastatic claudin 18.2-positive, PD-L1-positive GE cancer (15:34) CME information and select publications

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Samuel Klempner from Massachusetts General Hospital in Boston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, and Dr John Strickler from Duke University in Durham, North Carolina, review relevant data supporting immunotherapy for patients with gastroesophageal cancers and recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Prof Karim Fizazi from the Centre Oscar Lambret in Lille, France, Dr Daniel George from the Duke Cancer Institute in Durham, North Carolina, and moderator Dr Elisabeth I Heath from Mayo Clinic in Rochester, Minnesota, discuss the future role of AKT inhibition in prostate cancer.CME information and select publications here.

Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics: Introduction (0:00) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25) Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54) Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15) CME information and select publications

What if the secret to thriving in life and business could be learned from the baseball diamond?In this powerful episode of Thrive LouD, Lou Diamond welcomes back acclaimed baseball writer and author Ken Davidoff for an eye-opening conversation about his newest book, "101 Lessons from the Dugout: What Baseball and Softball Can Teach Us About the Game of Life."Fittingly recorded LIVE in studio on Opening Day!!Discover why Ken Davidoff walked away from a 30-year sportswriting career at the top of his game and how a random call from his agent opened the door to a new adventure in teaching, mentoring, and authorship. The episode dives deep into how the life lessons found between the foul lines can impact coaches, parents, leaders, and young athletes alike. Hear the behind-the-scenes stories about crafting the book alongside pediatrician Dr. Harley Rothbard, the power of collaboration, and the surprising writing process that turned daily deadlines into an enjoyable pursuit.You'll also hear Ken Davidoff's Mount Rushmore of greatest games he ever covered (some with national, historic significance), what he misses most about journalism, and, of course, the real-life lesson from the game that changed his approach forever.Episode Timestamps:[00:00] Introduction and welcome[00:42] Ken Davidoff's background in baseball journalism[02:09] Adjunct teaching and career shift[02:41] Why Ken Davidoff left sportswriting and how the book project began[03:23] Blending perspectives: the inspiration behind "101 Lessons from the Dugout"[04:11] Translating baseball lessons to life and the story of the “stretch”[05:44] Who the book is for—players, coaches, parents, leaders[06:47] Pro athletes, leadership, and lessons for players[08:06] Ken Davidoff's writing process and collaboration with his co-author[09:30] Editing the book and feedback process[11:25] Lessons that didn't make the cut[12:03] Promoting the book and leveraging relationships[13:11] What Ken Davidoff misses (and doesn't miss) about journalism[14:42] Is there another book on the way?[15:21] Where to find Ken Davidoff and the book[16:21] Fun Street: favorite sports moments, activities, and lessons[22:13] Ken Davidoff's favorite life lesson: "Small Ball"[23:26] Personal memorabilia and closing thoughts[25:19] Outro and where to connectGet ready to see the game—and life itself—in a whole new way!

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Neoadjuvant immunotherapy for localized rectal cancer (0:00) Surveillance in neoadjuvant immunotherapy for localized rectal cancer (8:14) Determining a treatment strategy for resectable colon cancer (12:35) CME information and select publications

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Featuring perspectives from Dr Matthew D Galsky, Dr Shilpa Gupta, Dr Terence Friedlander and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Introduction (0:00) Optimal Use of Anti-PD-1/PD-L1 Antibodies in Non-Muscle-Invasive Bladder Cancer — Dr Friedlander (2:27) Evolving Management of Muscle-Invasive Bladder Cancer — Dr Gupta (33:30) Current and Future Role of Novel Intravesical Therapies in Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (1:01:56) Emerging Utility of Circulating Tumor DNA Evaluation in Nonmetastatic UBC — Dr Galsky (1:32:47) CME information and select publications

Dr Matthew D Galsky from The Tisch Cancer Institute in New York, New York, Dr Shilpa Gupta from Cleveland Clinic's Taussig Cancer Institute in Ohio, Prof Andrea Necchi from IRCCS San Raffaele Hospital in Milan, Italy, and moderator Dr Terence Friedlander from the University of California, San Francisco discuss recent data surrounding the management of non-muscle-invasive and muscle-invasive bladder cancer, alongside their perspectives on clinical application and disease management.CME information and select publications here.

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics: Younger patient with metastatic HER2-positive, PD-L1-positive gastric cancer (0:00) Older patient with metastatic HER2-positive gastroesophageal (GE) cancer (8:13) Clinical applications for zanidatamab in GE cancer (13:58) CME information and select publications

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and moderator Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.

Amazing Professors 3/24/26: (Tuesday's co-host: UMass Prof Amilcar Shabazz) Princeton History Prof Rhae Lynn Barnes on “Darkology: Blackface and the American Way of Entertainment.” Sci-Tech Café w/ MHC Prof Kirsten Norstrom & Hampshire Prof Juliet Johnston: “Everyone Poops…” and what to do with it. Gfld City Council Pres Lora Wondoloski: budget fights & single-stream recycling. Duke Goldman, UMass Adjunct Prof, on college & professional sports gambling.

In part two of this series, Dr. Aaron Zelikovich discusses the clinical implications for patients with HSV encephalitis.  Show citation:  Solomon T, Hooper C, Easton A, et al. Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. Lancet Neurol. 2026;25(2):136-146. doi:10.1016/S1474-4422(25)00454-5 

The Olivetti Programma 101 isn't quite like any other machine. On first glance it looks like a big desktop calculator. Inside, it's a purebred computer... but strange one. It uses twisted spring steel for memory, has no addresses, and it's machine code looks more like a spell than a program. It's existence is due, in no small part, to a man being very mean to GE engineers. Like Advent of Computing? Then check out the after show! Adjunct of Computing is now LIVE: YouTube Spotify Apple Podcasts

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Novel immune checkpoint inhibitors (0:00) Gastroesophageal junction cancer (7:36) Gastric cancer (14:52) CME information and select publications

Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.

Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.

In part one of this series, Dr. Aaron Zelikovich discusses the trial design and primary results.  Show citation:  Solomon T, Hooper C, Easton A, et al. Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. Lancet Neurol. 2026;25(2):136-146. doi:10.1016/S1474-4422(25)00454-5  Show transcript:  Dr. Aaron Zelikovich:  Welcome to today's Neurology Minute. My name is Aaron Zelikovich. I'm a neuromuscular specialist at Lenox Hill Hospital in New York City. Today, we'll discuss part one of a three-part series reviewing a recent article titled Safety and Efficacy of Adjunct Dexamethasone in Adults with Herpes Simplex Virus Encephalitis in the United Kingdom (DexEnceph) Study, a multicenter observer-blind randomized phase three control trial published in Lancet Neurology. In the first episode, we'll focus on the trial design and primary results. In part two, we'll discuss the clinical implications for patients with HSV encephalitis, and in part three, discuss the outcomes seen across the trial during and after an acute infection. Overall, the study found that adjunct dexamethasone did not improve outcomes in patients with CSF-confirmed HSV encephalitis. But importantly, it also did not worsen outcomes. Prior research that was non-randomized and retrospective of 45 patients with HSV encephalitis found that patients did not receive corticosteroids had worse outcomes. A different randomized trial looking at dexamethasone and HSV encephalitis was only able to recruit 41 patients and was stopped prematurely due to the lack of recruitment. Prior to the study, there was no clear evidence that adjunct steroids with acyclovir improved outcomes in HSV encephalitis. The Dex and phase three randomized clinical trial performed in the United Kingdom at 53 hospitals recruited patients from 2016 to 2022. They screened over 1,400 patients of which only 94, or 6%, were enrolled. Patients were randomized to either acyclovir only or acyclovir and intravenous dexamethasone. In order to be randomized, patients had to have a febrile illness with new onset seizure or new focal neurological sign or altered mental status as well as a positive HSV type one or two PCR from the CSF. The primary outcome for this study was the Wechsler Memory Scale Type Four Auditory Memory Index Score which was collected at 26 weeks. It had a range of 40, which is the worst outcome, to a range of 160 which was considered normal. 81 patients were included in the modified intention-to-treat analysis. Of the 13 patients, six were lost to follow-up, and seven withdrew consent. There were 39 patients in the dexamethasone group and 42 in the acyclovir-only group in the final analysis. The primary outcome of the Wechsler Memory Scale had similar scores in both groups. 71 in the dexamethasone group and 69 in the control group with a P value of 0.76. The safety profile was similar in both groups, and there were no additional safety signals found in the dexamethasone-treated group. At 26 weeks, there were 12 deaths from HSV encephalitis, six from each group, as well as a similar time to discharge between both cohorts. The DexEnceph clinical trial did not show any clear clinical benefit for dexamethasone with regards to clinical outcomes but also didn't show any increased safety concerns compared to only acyclovir. In part two, we will discuss the implications of this trial in patients with undifferentiated encephalitis and the role that steroids play in patients that HSV encephalitis is suspected. Thank you so much, and have a wonderful day.   

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Biliary tract cancer progressing on first-line therapy (0:00) Gallbladder cancer (5:01) Biliary tract cancer with multiple biomarker targets (8:52) CME information and select publications